LXRX Quote, Financials, Valuation and Earnings

Capricor Therapeutics has a net margin of -2004.36% compared to Lexicon Pharmaceuticals's net margin of -63.94%. Lexicon Pharmaceuticals's return on equity of -90.8% beat Capricor Therapeutics's return on equity of -75.99%.

Lexicon Pharmaceuticals has a consensus price target of $2.58, signalling upside risk potential of 100%. On the other hand Capricor Therapeutics has an analysts' consensus of $20.60 which suggests that it could grow by 184.53%. Given that Capricor Therapeutics has higher upside potential than Lexicon Pharmaceuticals, analysts believe Capricor Therapeutics is more attractive than Lexicon Pharmaceuticals.

Lexicon Pharmaceuticals has a beta of 1.129, which suggesting that the stock is 12.928% more volatile than S&P 500. In comparison Capricor Therapeutics has a beta of 0.820, suggesting its less volatile than the S&P 500 by 18.02%.

Lexicon Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Capricor Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lexicon Pharmaceuticals pays -- of its earnings as a dividend. Capricor Therapeutics pays out -- of its earnings as a dividend.

Lexicon Pharmaceuticals quarterly revenues are $1.3M, which are smaller than Capricor Therapeutics quarterly revenues of $11.1M. Lexicon Pharmaceuticals's net income of -$25.3M is lower than Capricor Therapeutics's net income of -$24.4M. Notably, Lexicon Pharmaceuticals's price-to-earnings ratio is -- while Capricor Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lexicon Pharmaceuticals is 14.43x versus 12.59x for Capricor Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

ClearPoint Neuro has a net margin of -2004.36% compared to Lexicon Pharmaceuticals's net margin of -71.02%. Lexicon Pharmaceuticals's return on equity of -90.8% beat ClearPoint Neuro's return on equity of -73.69%.

Lexicon Pharmaceuticals has a consensus price target of $2.58, signalling upside risk potential of 100%. On the other hand ClearPoint Neuro has an analysts' consensus of $29.00 which suggests that it could grow by 155.96%. Given that ClearPoint Neuro has higher upside potential than Lexicon Pharmaceuticals, analysts believe ClearPoint Neuro is more attractive than Lexicon Pharmaceuticals.

Lexicon Pharmaceuticals has a beta of 1.129, which suggesting that the stock is 12.928% more volatile than S&P 500. In comparison ClearPoint Neuro has a beta of 0.917, suggesting its less volatile than the S&P 500 by 8.296%.

Lexicon Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ClearPoint Neuro offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lexicon Pharmaceuticals pays -- of its earnings as a dividend. ClearPoint Neuro pays out -- of its earnings as a dividend.

Lexicon Pharmaceuticals quarterly revenues are $1.3M, which are smaller than ClearPoint Neuro quarterly revenues of $8.5M. Lexicon Pharmaceuticals's net income of -$25.3M is lower than ClearPoint Neuro's net income of -$6M. Notably, Lexicon Pharmaceuticals's price-to-earnings ratio is -- while ClearPoint Neuro's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lexicon Pharmaceuticals is 14.43x versus 9.69x for ClearPoint Neuro. Usually stocks with elevated PS ratios are considered overvalued.

Inovio Pharmaceuticals has a net margin of -2004.36% compared to Lexicon Pharmaceuticals's net margin of -30140.49%. Lexicon Pharmaceuticals's return on equity of -90.8% beat Inovio Pharmaceuticals's return on equity of -125.47%.

Lexicon Pharmaceuticals has a consensus price target of $2.58, signalling upside risk potential of 100%. On the other hand Inovio Pharmaceuticals has an analysts' consensus of $7.50 which suggests that it could grow by 459.7%. Given that Inovio Pharmaceuticals has higher upside potential than Lexicon Pharmaceuticals, analysts believe Inovio Pharmaceuticals is more attractive than Lexicon Pharmaceuticals.

Lexicon Pharmaceuticals has a beta of 1.129, which suggesting that the stock is 12.928% more volatile than S&P 500. In comparison Inovio Pharmaceuticals has a beta of 1.307, suggesting its more volatile than the S&P 500 by 30.734%.

Lexicon Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Inovio Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lexicon Pharmaceuticals pays -- of its earnings as a dividend. Inovio Pharmaceuticals pays out -- of its earnings as a dividend.

Lexicon Pharmaceuticals quarterly revenues are $1.3M, which are larger than Inovio Pharmaceuticals quarterly revenues of $65.3K. Lexicon Pharmaceuticals's net income of -$25.3M is lower than Inovio Pharmaceuticals's net income of -$19.7M. Notably, Lexicon Pharmaceuticals's price-to-earnings ratio is -- while Inovio Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lexicon Pharmaceuticals is 14.43x versus -- for Inovio Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Semler Scientific has a net margin of -2004.36% compared to Lexicon Pharmaceuticals's net margin of -732.34%. Lexicon Pharmaceuticals's return on equity of -90.8% beat Semler Scientific's return on equity of -23.56%.

Lexicon Pharmaceuticals has a consensus price target of $2.58, signalling upside risk potential of 100%. On the other hand Semler Scientific has an analysts' consensus of $98.00 which suggests that it could grow by 129.46%. Given that Semler Scientific has higher upside potential than Lexicon Pharmaceuticals, analysts believe Semler Scientific is more attractive than Lexicon Pharmaceuticals.

Lexicon Pharmaceuticals has a beta of 1.129, which suggesting that the stock is 12.928% more volatile than S&P 500. In comparison Semler Scientific has a beta of 1.392, suggesting its more volatile than the S&P 500 by 39.164%.

Lexicon Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Semler Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lexicon Pharmaceuticals pays -- of its earnings as a dividend. Semler Scientific pays out -- of its earnings as a dividend.

Lexicon Pharmaceuticals quarterly revenues are $1.3M, which are smaller than Semler Scientific quarterly revenues of $8.8M. Lexicon Pharmaceuticals's net income of -$25.3M is higher than Semler Scientific's net income of -$64.7M. Notably, Lexicon Pharmaceuticals's price-to-earnings ratio is -- while Semler Scientific's PE ratio is 8.32x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lexicon Pharmaceuticals is 14.43x versus 7.32x for Semler Scientific. Usually stocks with elevated PS ratios are considered overvalued.